Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

Inclusion Criteria

• •The patient has biopsy-confirmed diagnosis of indolent B-cell NHL documented as relapsed or refractory iNHL (following rituximab-based therapy).
• •The patient has one of the following types of indolent B-cell lymphoma:
• •* follicular lymphoma grade 1, 2, or 3A
• •* marginal zone lymphoma
• •* lymphoplasmacytic lymphoma
• •* small lymphocytic lymphoma
• •The patient has adequate haematologic function (unless abnormalities are related to lymphoma involvement of the bone marrow or hypersplenism caused by lymphoma).
• •The patient has previously confirmed (according to WHO criteria) untreated symptomatic chronic B-cell lymphocytic leukemia Binet Stage B or Binet Stage C or Rai stage II to IV in need of medical treatment.
• •The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.